ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

penpulimab

Also written as “AK105”, “Penpulimab” and “Penpulimab injection”.

Its studies are mostly in Carcinoma, Hepatocellular · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Hodgkin Disease · Esophageal Squamous Cell Carcinoma, led by 2 companies.

Drug pagePenpulimab: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 10, 202027 company-led studies, 9 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceuticalits history only187 open or runningphase 3since Apr 10, 2020Dec 17, 2019Dec 2026phase 3 · NCT04344158
Akeso92 open or runningphase 3since Mar 6, 2019Nov 21, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Akeso only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 21, 2017First study: phase 1 study in Advanced CancerFirst studyNCT03352531 · 99 enrolled · Australia
  2. Oct 25, 2018Phase 2 study in Hodgkin DiseaseNCT03722147 · 94 enrolled · China
  3. Mar 6, 20192 phase 3 studies in Carcinoma, Non-Small-Cell LungNCT03866993, NCT03866980
  4. Mar 6, 2019Phase 2 study in Nasopharyngeal CarcinomaNCT03866967 · 130 enrolled · China
  5. Nov 19, 20192 phase 2 studiesNCT04172571, NCT04172506
  6. Jun 9, 2020Named penpulimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, AK105
  7. Jul 13, 2021Phase 3 study in Nasopharyngeal CarcinomaNCT04974398 · 296 enrolled · United States, Australia, Brazil and more
  8. Jan 25, 2022Phase 3 study in Hodgkin Disease LymphomaNCT05244642 · 60 planned · China

TargetBeta

PDCD1 →read by rule
“A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 9 Akeso leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05244642Hodgkin Disease Lymphoma · China3RecruitingDec 30, 202560
NCT04974398Nasopharyngeal Carcinoma · United States, Australia, Brazil and more3Active, not recruitingFeb 23, 2026296
NCT04172571Carcinoma, Hepatocellular · China2CompletedJun 1, 202231
NCT04172506Lung Neoplasms · China2CompletedDec 1, 202165
NCT03866993Carcinoma, Non-Small-Cell Lung · China3CompletedOct 8, 2020350
NCT03866980Carcinoma, Non-Small-Cell Lung · China3TerminatedJun 30, 2023164
NCT03866967Nasopharyngeal Carcinoma · China2CompletedMar 13, 2021130
NCT03722147Hodgkin Disease · China2CompletedJan 10, 202094
NCT03352531Advanced Cancer · Australia1CompletedNov 30, 202099

How it is read

Names in the registry

  • “AK105”, 9 entries
  • “Penpulimab”, 3 entries
  • “Penpulimab injection”, 2 entries
  • “AK105 injection”, 2 entries
  • “TQB2618 injection; Penpulimab injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.